PD1 CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non-Hodgkin's lymphoma
Latest Information Update: 25 Jun 2019
At a glance
- Drugs ICTCAR 014 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Innovative Cellular Therapeutics
Most Recent Events
- 25 Jun 2019 New trial record